Search Results - "Pipe, S W"

Functional roles of the factor VIII B domain by PIPE, S. W.

“…Unravelling the structure, function and molecular interactions of factor VIII (FVIII) throughout its life cycle from biosynthesis to clearance has advanced our…”
Get full text

The promise and challenges of bioengineered recombinant clotting factors by PIPE, S. W.

“…The past 10 years of clinical experience have demonstrated the safety and efficacy of recombinant clotting factors. With the adoption of prophylactic…”
Get full text

Bioengineered molecules for the management of haemophilia: Promise and remaining challenges by Pipe, S. W.

“…Recombinant DNA technology has led to accelerating introduction of novel therapeutics for the treatment of haemophilia. This technology has driven the…”
Get full text

Progress in the molecular biology of inherited bleeding disorders by PIPE, S. W., HIGH, K. A., OHASHI, K., URAL, A. U., LILLICRAP, D.

Get full text

Advantage of recombinant von Willebrand factor for peri‐operative management in paediatric acquired von Willebrand syndrome by Weyand, A. C., Jesudas, R., Pipe, S. W.

Get full text

Strategies towards a longer acting factor VIII by SAENKO, E. L., PIPE, S. W.

“…The reduced mortality, improved joint outcomes and enhanced quality of life, which have been witnessed in the developed world for patients with haemophilia,…”
Get full text

Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis by Valentino, L. A., Pipe, S. W., Collins, P. W., Blanchette, V. S., Berntorp, E., Fischer, K., Ewenstein, B. M., Oh, M., Spotts, G.

“…Introduction We previously showed that pharmacokinetic‐guided prophylaxis (PKP) allows the dosing interval to be extended while maintaining a specific trough…”
Get full text

Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation : Evidence for nonproteolytic inactivation of factor VIIIa in vivo by PIPE, S. W, EICKHORST, A. N, MCKINLEY, S. H, SAENKO, E. L, KAUFMAN, R. J

“…Approximately 5% of hemophilia A patients have normal amounts of a dysfunctional factor VIII (FVIII) protein and are termed cross-reacting material…”
Get full text

SAFETY AND EFFICACY OF THE FITUSIRAN REVISED ANTITHROMBIN-BASED DOSE REGIMEN IN PEOPLE WITH HAEMOPHILIA A OR B, WITH OR WITHOUT INHIBITORS (ATLAS-OLE) by Guy-Young, Kaan-Kavakli, S W-Pipe, Alok-Srivastava, Juliana-Aragao, L A-Menapace, Chuanwu-Zhang, Marja-Puurunen, Marek-Demissie, Gili-Kenet

“…Background: Fitusiran, a Subcutaneous (SC) investigational siRNA therapeutic, lowers Antithrombin (AT) to increase thrombin generation and rebalance…”
Get full text

International workshop on immune tolerance induction: consensus recommendations by DIMICHELE, D. M., HOOTS, W. K., PIPE, S. W., RIVARD, G. E., SANTAGOSTINO, E.

“…Although immune tolerance induction (ITI) has been used for 30 years to eliminate inhibitors and restore normal factor pharmacokinetics in patients with…”
Get full text

Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors—A retrospective analysis by Carcao, M., Shapiro, A., Staber, J. M., Hwang, N., Druzgal, C., Lieuw, K., Belletrutti, M., Thornburg, C. D., Ahuja, S. P., Morales‐Arias, J., Dumont, J., Miyasato, G., Tsao, E., Jain, N., Pipe, S. W.

“…Introduction Immune tolerance induction (ITI) is the gold standard for eradication of factor VIII inhibitors in severe haemophilia A; however, it usually…”
Get full text

Minimal dataset for post‐registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH by Peyvandi, F., Makris, M., Collins, P., Lillicrap, D., Pipe, S. W., Iorio, A., Rosendaal, F. R.

Get full text

Evidence-based guidelines support integrated disease management as the optimal model of haemophilia care by Pipe, S. W., Kessler, C. M.

Get full text

SURGICAL EXPERIENCE IN PEOPLE WITH HEMOPHILIA A OR B WITH AND WITHOUT INHIBITORS RECEIVING FITUSIRAN by Alok-Srivastava, Pencho-Georgiev, Toshko-Lissitchkov, M V-Ragni, Juliana-Aragao, L A-Menapace, Yuqian-Shen, Marja-Puurunen, Marek-Demissie, S W-Pipe

“…Background: Fitusiran, a subcutaneous, investigational siRNA therapeutic lowers antithrombin to rebalance hemostasis and enhance thrombin generation in People…”
Get full text

Adherence to prophylactic infusions of factor VIII or factor IX for haemophilia by THORNBURG, C. D., PIPE, S. W.

Get full text

Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies by Pierce, G. F., Ragni, M. V., Berg, H. M., Weill, A., O'Mahony, B., Skinner, M. W., Pipe, S. W.

Get full text

GLOBAL COMPARATIVE ANTITHROMBIN-FIELD STUDY: IMPACT OF LABORATORY ASSAY VARIABILITY ON THE ASSESSMENT OF ANTITHROMBIN ACTIVITY MEASUREMENT by E Seth-Chhabra, A Sadeghi-Khomami, Mingjie-Liu, Guy-Young, S W-Pipe, MC Ozelo, C Le-Camus, M Toh, SA Lima-Montalvao, Marek-Demissie

“…Objectives: Fitusiran is an investigational, subcutaneous small interfering RNA therapeutic in development for hemophilia A and B, with and without inhibitors…”
Get full text

Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin by Metzner, H J, Pipe, S W, Weimer, T, Schulte, S

“…The prophylactic treatment of haemophilia B and the management of haemophilia A or B with inhibitors demand frequent administrations of coagulation factors due…”
Get more information

Prophylactic therapy with Fibrogammin® P is associated with a decreased incidence of bleeding episodes: a retrospective study by LUSHER, J., PIPE, S. W., ALEXANDER, S., NUGENT, D.

“…Congenital factor XIII (FXIII) deficiency is an extremely rare, yet potentially life‐threatening, bleeding disorder, with a 30% rate of spontaneous…”
Get full text

Lactadherin blocks thrombosis and hemostasis in vivo: correlation with platelet phosphatidylserine exposure by SHI, J., PIPE, S. W., RASMUSSEN, J. T., HEEGAARD, C. W., GILBERT, G. E.

“…Background: Platelet membrane phosphatidylserine (PS) is considered to be essential for hemostasis and thrombosis, but the in vivo topography of platelet PS…”
Get full text